Dr. Sahenk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
700 Childrens Dr
Columbus, OH 43205Phone+1 614-355-3574Fax+1 614-722-3273- Is this information wrong?
Education & Training
Ohio State University HospitalResidency, Neurology, 1975 - 1978- Ohio State University HospitalResidency, Internal Medicine, 1974 - 1975
- Ohio State University HospitalResidency, Physical Medicine and Rehabilitation, 1972 - 1974
Hacettepe University FOMClass of 1972
Certifications & Licensure
OH State Medical License 1978 - 2026
IL State Medical License 1977 - 1984- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A Start of enrollment: 2023 Aug 01
- NT-3 Levels and Function in Individuals With CMT Start of enrollment: 2019 Nov 13
Publications & Presentations
PubMed
- 1 citationsLesion level-dependent systemic muscle wasting after spinal cord injury is mediated by glucocorticoid signaling in mice.Harrigan, M., Markus E Harrigan, Angela R Filous, Christopher P Vadala, Amy Webb, Maciej Pietrzak, Zarife Sahenk, Harald Prüss, Peter J Reiser, Phillip G Popovich, W D...> ;Science Translational Medicine. 2023 Dec 20
- 3 citationsLong-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.Jerry R Mendell, Zarife Sahenk, Kelly J Lehman, Linda P Lowes, Natalie F Reash, Megan A Iammarino, Lindsay N Alfano, Sarah Lewis, Kathleen Church, Richard Shell, Racha...> ;Muscle & Nerve. 2024 Jan 1
- 1 citationsAAV1.NT-3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia.Lingying Tong, Burcak Ozes, Kyle Moss, Morgan Myers, Alicia Ridgley, Zarife Sahenk> ;Journal of Cachexia, Sarcopenia and Muscle. 2023 Oct 1
- Join now to see all
Journal Articles
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, Richard Shell, JAMA Neurology
Authored Content
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJune 2020
Press Mentions
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2ASeptember 3rd, 2021- First Global CMT Research Convention Planned for SeptemberJune 16th, 2021
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to Its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular DystrophyMay 8th, 2019- Join now to see all
Grant Support
- NT-3 Gene Therapy To Improve Peripheral Nerve Function Induced By Genetic DefectNational Institute Of Neurological Disorders And Stroke2010–2011
- Histopathology CoreEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
- Histopathology CoreNational Institute Of Neurological Disorders And Stroke2007–2010
Professional Memberships
- Member
Hospital Affiliations
Nationwide Children's HospitalColumbus, Ohio
Ohio State University Wexner Medical CenterColumbus, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
